This proposal will test the utility of a stress- inducible cellular promoter to drive expression of therapeutic genes to induce regression and immune rejection of solid tumors. The approach is based on the observation that stress proteins, known as glucose regulated proteins (GRP), are overexpressed in solid tumors, protecting stressed cells from apoptosis. The ability of the grp78 promoter is utilized to drive expression of therapeutic genes in tumors, starved for glucose and oxygen, to facilitate tumor regression. The HSV thymidine kinase gene (HSVtk) under control of the grp78 promoter is induced in stressed cells, making cells exquisitely sensitive to the action of ganciclovir (GCV). We had established that tumors transduced with a retroviral vector containing the HSVtk gene driven by the grp78 promoter regress in mice treated with GCV. Further, we have shown that immune memory is induced against the regressing tumor. These observations raise the question as to the usefulness of stress inducible promoters as a tool for gene therapy of solid tumors. The goal of this proposal is to test the affectivity of this strategy in in vivo tumor models in mice. We have shown that tumors transduced with a therapeutic gene construct regress in animals treated with GCV but the question needs to be answered whether tumors, not transduced with the therapeutic gene may regress concomitantly. Regression of non-transduced tumors requires a specific recognition event of either the adaptive cell mediated immune system or by the natural immune system. Experiments are proposed in immunocompetent animals or animals depleted of specific immune effectors. The vector, currently used to transduce tumor cells is a first generation design which has shown promising effects in vivo. We will test this promoter construct for its efficiency in various tumor models and propose to introduce modifications to this design to make it more efficient for induction of tumor regression. The modifications will include elimination of the remaining basal control elements in the grp78 promoter, used in the current construct to achieve more stringent gene expression and inclusion of therapeutic genes. Modifications to be incorporated into these constructs will include CD8O, a ligand that stimulates sensitization of T cells and GM-CSF a cytokine which stimulates antigen presenting cells with the overall goal in mind to induce a response to weak tumor specific epitopes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA059318-08
Application #
6598171
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-06-05
Project End
2003-02-28
Budget Start
Budget End
Support Year
8
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90033
Perez, Omar D; Logg, Christopher R; Hiraoka, Kei et al. (2012) Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther 20:1689-98
Christodoulopoulos, Ilias; Droniou-Bonzom, Magali E; Oldenburg, Jill E et al. (2010) Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors. Retrovirology 7:4
Epand, Raquel F; Zhang, Yan-Liang; Mirzabekov, Tajib et al. (2008) Membrane activity of an amphiphilic alpha-helical membrane-proximal cytoplasmic domain of the MoMuLV envelope glycoprotein. Exp Mol Pathol 84:9-17
Rozenberg-Adler, Yanina; Conner, John; Aguilar-Carreno, Hector et al. (2008) Membrane-proximal cytoplasmic domain of Moloney murine leukemia virus envelope tail facilitates fusion. Exp Mol Pathol 84:18-30
Logg, Christopher R; Baranick, Brian T; Lemp, Nathan A et al. (2007) Adaptive evolution of a tagged chimeric gammaretrovirus: identification of novel cis-acting elements that modulate splicing. J Mol Biol 369:1214-29
Hiraoka, Kei; Kimura, Takahiro; Logg, Christopher R et al. (2007) Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Res 67:5345-53
Weber, Erin L; Cannon, Paula M (2007) Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential. Hum Gene Ther 18:849-60
Kikuchi, Eiji; Menendez, Silvia; Ozu, Choichiro et al. (2007) Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors. Clin Cancer Res 13:4511-8
Hsu, Faye Yuan-yi; Zhao, Yi; Anderson, W French et al. (2007) Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro. Cancer Invest 25:240-8
Kikuchi, E; Menendez, S; Ozu, C et al. (2007) Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Cancer Gene Ther 14:279-86

Showing the most recent 10 out of 70 publications